Biomarkers in Idiopathic Pulmonary Fibrosis

Stanković, Sanja; Stjepanović, Mihailo; Ašanin, Milika

doi:10.5772/intechopen.100042

Cited by 3 publications

(19 citation statements)

References 212 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neke zemlje imaju registar ovih bolesti, ali se postavlja pitanje koliko su validni ti registri, jer su podaci krajnje oprečni. Prema dostupnim podacima, najčešće inetersticijumske bolesti su sarkoidoza i idiopatska plućna fibroza (čine preko 50% ILD-a) [5].…”

Section: Uvodunclassified

See 1 more Smart Citation

Interstitial lung diseases and secondary pulmonary hypertension

Belić¹,

Marić²,

Đurđević³

et al. 2023

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

Interstitial lung disease alone can have a poor prognosis, and when associated with pulmonary hypertension there is a significant reduction in survival rates. Since the incidence of pulmonary hypertension in patients with interstitial lung diseases is very high and the symptoms are similar and often unrecognized, our aim is to point out the significance of both coexisting diseases and to prompt clinicians to suspect pulmonary hypertension. Through a brief review of the pathohistological changes, diagnostic methods, and the clinical presentation of these diseases, the similarities and differences that can help in the management of these patients, are shown. The latest treatment guidelines, with a special focus on the impact of antifibrotic treatment (nintedanib and pirfenidone) on pulmonary hypertension, are presented.

show abstract

Section: Uvodunclassified

“…Some countries have a registry of these diseases, however, the issue remains as to the validity of these registries, as the data are quite contradictory. According to available data, the most frequent interstitial diseases are sarcoidosis and idiopathic pulmonary fibrosis (they account for over 50% of ILDs) [5].…”

Section: Introductionmentioning

confidence: 99%

Interstitial lung diseases and secondary pulmonary hypertension

Belić¹,

Marić²,

Đurđević³

et al. 2023

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

show abstract

“…Signs of epithelial cell damage hold promise as diagnostic and prognostic biomarkers for IPF, consequently offering valuable support in its clinical care [23]. The main biomarkers associated with alveolar epithelial cell dysfunction are represented by Krebs von den Lungen 6 (KL-6), surfactant proteins, mucin 5B (MUC5B), oncomarkers (CA 15-3, CA 125, CA 19-9, and CEA), Clara cell secretory protein (CC16), telomeres shortening, cleaved cytokeratin 18 (cCK-18), alpha-v beta-6 (αvβ6), and alpha-v beta-1 (αvβ1) integrin [13,22,24].…”

Section: Biomarkersmentioning

confidence: 99%

“…Nevertheless, the existence of MUC5B rs35705950 had no concrete effect on the treatment outcome with nintedanib or pirfenidone, but it suggests a higher survival rate in patients affected by IPF [47,48]. Up to this point, research has highlighted that IPF and lung cancer are similar in some particular aspects, from genetic and epigenetic markers, to risk factors (age, smoking, and work-related or environmental exposure) and several disturbances that occur in the molecules and cells involved in cellular communication pathways [13,49].…”

Section: The Mucin Muc5bmentioning

confidence: 99%

“…With the advent of antifibrotic drugs, early IPF diagnosis became essential in order to preserve the quality of life; therefore, biomarkers usable for risk assessment, early detection, prognosis, or management of the disease became necessary and sought after [11]. Potential biomarkers might reflect various biological phenomena: alveolar epithelial cell damage and dysfunction, extracellular matrix remodeling, fibroblast proliferation, and immune dysfunction/inflammation [12,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the Role of Biomarkers Associated with Alveolar Damage and Dysfunction in Idiopathic Pulmonary Fibrosis—A Systematic Review

Zamfir,

Zabara,

Arcana

et al. 2023

JPM

View full text Add to dashboard Cite

Background: Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of interstitial lung diseases (ILDs), marked by an ongoing, chronic fibrotic process within the lung tissue. IPF leads to an irreversible deterioration of lung function, ultimately resulting in an increased mortality rate. Therefore, the focus has shifted towards the biomarkers that might contribute to the early diagnosis, risk assessment, prognosis, and tracking of the treatment progress, including those associated with epithelial injury. Methods: We conducted this review through a systematic search of the relevant literature using established databases such as PubMed, Scopus, and Web of Science. Selected articles were assessed, with data extracted and synthesized to provide an overview of the current understanding of the existing biomarkers for IPF. Results: Signs of epithelial cell damage hold promise as relevant biomarkers for IPF, consequently offering valuable support in its clinical care. Their global and standardized utilization remains limited due to a lack of comprehensive information of their implications in IPF. Conclusions: Recognizing the aggressive nature of IPF among interstitial lung diseases and its profound impact on lung function and mortality, the exploration of biomarkers becomes pivotal for early diagnosis, risk assessment, prognostic evaluation, and therapy monitoring.

show abstract

Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?

Singh,

Ulasov,

Gupta

et al. 2024

Discovery Medicine

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis is a progressive and incurable lung disease characterized by collagen deposition, alveolar inflammation, fibroblast proliferation, and the destruction of lung tissue structures. It is a rare yet severe condition with a high mortality rate, typically leading to death within 3-5 years of diagnosis. The clinical presentation of idiopathic pulmonary fibrosis (IPF) involves a gradual and substantial loss of lung function, ultimately resulting in respiratory failure. Despite more than half a century of intensive research, the origin of IPF remains a mystery. Despite its unknown etiology, several genetic and non-genetic factors have been linked to IPF. Recent significant advancements have been made in the field of IPF diagnosis and treatment. Two oral small-molecule drugs, pirfenidone and nintedanib, have recently gained approval for the treatment of IPF. Pirfenidone exhibits antifibrotic, antioxidant, and anti-inflammatory properties, while nintedanib is a tyrosine kinase inhibitor with selectivity for vascular endothelial growth factor (VEGF) receptors, prostaglandin F (PGF) receptors, and fibroblast growth factor (FGF) receptors. Both of these compounds are capable of slowing down the progression of the disease with an acceptable safety profile. This review provides a brief introduction, historical background, epidemiological insights, and an exploration of various environmental risk factors that may influence the lung microenvironment and contribute to the advancement of IPF. The review also delves into the diagnosis, signaling pathways, and ongoing clinical trials worldwide. A thorough review of the literature was conducted using PubMed and Google Scholar to gather information on various aspects of IPF. Numerous potential drugs are currently under investigation in clinical trials, and the completion of this process is crucial to the ultimate goal of finding a cure for IPF patients. The investigation of the role of genes, surfactant proteins, infectious agents, biomarkers, and epigenetic changes holds the promise of offering earlier and more accurate understanding and diagnosis of IPF. This information could be instrumental in the development of new therapeutic approaches for treating IPF and is expected to be of great interest to researchers.

show abstract

Biomarkers in Idiopathic Pulmonary Fibrosis

Cited by 3 publications

References 212 publications

Interstitial lung diseases and secondary pulmonary hypertension

Interstitial lung diseases and secondary pulmonary hypertension

Exploring the Role of Biomarkers Associated with Alveolar Damage and Dysfunction in Idiopathic Pulmonary Fibrosis—A Systematic Review

Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?

Contact Info

Product

Resources

About